ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.660
+0.090 (2.52%)
At close: Jan 9, 2026, 4:00 PM EST
3.660
0.00 (0.00%)
After-hours: Jan 9, 2026, 7:00 PM EST
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $16.43M in the quarter ending September 30, 2025, a decrease of -11.03%. This brings the company's revenue in the last twelve months to $75.21M, up 6.35% year-over-year. In the year 2024, ADC Therapeutics had annual revenue of $70.84M with 1.84% growth.
Revenue (ttm)
$75.21M
Revenue Growth
+6.35%
P/S Ratio
5.63
Revenue / Employee
$283,808
Employees
265
Market Cap
453.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.84M | 1.28M | 1.84% |
| Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
| Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
| Dec 31, 2021 | 33.92M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 2.34M | 1.20M | 105.26% |
| Dec 31, 2018 | 1.14M | -663.00K | -36.77% |
| Dec 31, 2017 | 1.80M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADCT News
- 1 day ago - ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates - PRNewsWire
- 1 day ago - ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 days ago - ADC Therapeutics Announces New Employee Inducement Grant - PRNewsWire
- 5 weeks ago - ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript - Seeking Alpha
- 5 weeks ago - ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - PRNewsWire
- 5 weeks ago - ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial - PRNewsWire
- 5 weeks ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 2 months ago - ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript - Seeking Alpha